E. D. Arisan Et Al. , "The molecular targets of diclofenac differs from ibuprofen to induce apoptosis and epithelial mesenchymal transition due to alternation on oxidative stress management p53 independently in PC3 prostate cancer cells," PROSTATE INTERNATIONAL , vol.7, no.4, pp.156-165, 2019
Arisan, E. D. Et Al. 2019. The molecular targets of diclofenac differs from ibuprofen to induce apoptosis and epithelial mesenchymal transition due to alternation on oxidative stress management p53 independently in PC3 prostate cancer cells. PROSTATE INTERNATIONAL , vol.7, no.4 , 156-165.
Arisan, E. D., Akar, R. O., Rencuzogullari, O., Yerlikaya, P. O., Gurkan, A., Akin, B., ... Dener, E.(2019). The molecular targets of diclofenac differs from ibuprofen to induce apoptosis and epithelial mesenchymal transition due to alternation on oxidative stress management p53 independently in PC3 prostate cancer cells. PROSTATE INTERNATIONAL , vol.7, no.4, 156-165.
Arisan, Elif Et Al. "The molecular targets of diclofenac differs from ibuprofen to induce apoptosis and epithelial mesenchymal transition due to alternation on oxidative stress management p53 independently in PC3 prostate cancer cells," PROSTATE INTERNATIONAL , vol.7, no.4, 156-165, 2019
Arisan, Elif D. Et Al. "The molecular targets of diclofenac differs from ibuprofen to induce apoptosis and epithelial mesenchymal transition due to alternation on oxidative stress management p53 independently in PC3 prostate cancer cells." PROSTATE INTERNATIONAL , vol.7, no.4, pp.156-165, 2019
Arisan, E. D. Et Al. (2019) . "The molecular targets of diclofenac differs from ibuprofen to induce apoptosis and epithelial mesenchymal transition due to alternation on oxidative stress management p53 independently in PC3 prostate cancer cells." PROSTATE INTERNATIONAL , vol.7, no.4, pp.156-165.
@article{article, author={Elif D. Arisan Et Al. }, title={The molecular targets of diclofenac differs from ibuprofen to induce apoptosis and epithelial mesenchymal transition due to alternation on oxidative stress management p53 independently in PC3 prostate cancer cells}, journal={PROSTATE INTERNATIONAL}, year=2019, pages={156-165} }